<DOC>
	<DOC>NCT00824421</DOC>
	<brief_summary>This is a 96 week study to determine if UK- 453,061 in combination with Truvada is as efficacious, safe and tolerable as efavirenz in combination with Truvada in HIV-1 infected patients who have not been previously treated with antiretroviral drugs.</brief_summary>
	<brief_title>A Study Of Different Doses Of UK-453, 061 Plus Truvada Compared To Efavirenz Plus Truvada In Patients Who Have Not Been Previously Treated For HIV-1</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Male or female at least 18 years of age available for a followup period of at least 96 weeks. HIV 1 RNA viral load of greater then 1,000 copies/mL Negative urine pregnancy test. Suspected or documented active, untreated HIV1 related opportunist infection or other condition requiring acute therapy at the time of randomization. Subjects with acute Hepatitis B and/or C within 30 days of randomization. Absolute CD4 count &lt;200 cells/mm3.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>HIV-1. Treatment Naive</keyword>
	<keyword>HIV Infections</keyword>
	<keyword>treatment naive</keyword>
</DOC>